SAN DIEGO, CA--(Marketwire - Feb 27, 2013) - Dr. Mathew Thakur, Thomas Jefferson University, will present data on the first "in human" test of cancer specific radiotracer Cu-64-TP3805. TP3805 is a compound that binds to the VPAC1 receptors expressed on all breast cancer cells early in malignant transformation. The goal of this compound is to provide "in vivo" imaging histologic confirmation of malignancy. WB PET-CT and Naviscan's high resolution organ-specific PET scanner, which when applied to breast imaging is called Positron Emission Mammography or PEM, were utilized in this study.
PEM imaging using both Cu-64-TP3805 and F-18-FDG was done in 13 patients. With TP3805, all malignant lesions (n=20) inclusive of lymph nodes with metastatic disease were identified using only 4 ± 10% mCi of Cu-64-TP3805 and imaging 15 minutes post-injection.
"There is a compelling need for a biomolecule that will noninvasively distinguish malignant from benign lesions," states Dr. Thakur. "Cu-64-TP3805 promises to be such an agent and warrants further studies in patients to validate the hypothesis that Cu-64-TP3805 will help reduce the number of unnecessary biopsies."
"We value the scientific breakthrough of Dr. Thakur and his colleagues," states Paul J. Mirabella, CEO, Naviscan, Inc. "Their clinical research validates the belief that molecular imaging can now be done with low radiation to the patient, fast imaging times and cancer specificity, thereby providing 'in vivo' cancer imaging histology. These results provide significant benefit to the patient by minimizing anxiety and invasive procedures such as biopsy, as well as potentially reducing healthcare costs."
The presentation titled "Can Ga-68 Contribute to the Welfare of Women Suspected to Have Breast Cancer?" will take place on February 28 from 2:25 p.m. - 2:45 p.m. in the auditorium at the 2nd World Congress on Ga-68, Molecular Imaging, Targeted Radionuclide Therapy and Dosimetry to be held February 28 - March 2, 2013 in Chandigarh, India.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, visit www.naviscan.com.